NewsRoom Articles - Page 80 of 154 - PsychedelicNewsWire (PNW)

ThursdayOct 28, 2021 12:30 pm

Psilocybin: Why and How It Should Be Rescheduled

Scientific and public interest in psychedelic substances such as MDMA and psilocybin has been growing, as more research on the substances is conducted. However, the federal prohibition of these substances has become a hindrance to the advancement of research on psychedelics, despite the commercial investment in psychedelic treatments and growing acceptance by the public. One of the most studied psychedelics is psilocybin, which is a compound that can be produced by many fungi species including hallucinogenic mushrooms. This compound was designated as a breakthrough therapy in 2018 and 2019 by the FDA, to acknowledge its safety as well as its…

WednesdayOct 27, 2021 2:15 pm

Harvard Law School Hosts Webinar to Discuss Psychedelics Policy Reform

A few weeks ago, advocates of psychedelic reform discussed the decriminalization of drugs and decreasing stigma surrounding the use of these substances during a webinar hosted by Harvard Law School. The webinar coincided with the launch of the Project on Psychedelics Law and Regulation by the Petrie-Flom Center for Health Policy. The project is a three-year initiative to study the social, legal and economic implications of psychedelic substances. Earl F. Blumenauer, a Democratic U.S. Representative in Congress and longtime marijuana reform advocate, stated in his opening remarks that he hopes that the historic progress on psychedelic decriminalization seen in Oregon…

WednesdayOct 27, 2021 9:30 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Is ‘One to Watch’

The Mydecine Innovations Group portfolio includes a robust portfolio of NCEs (New Chemical Entities) and medicines based on compounds found in psychedelics, including four lead clinical trial drug candidates, as well as digital health solutions Through an exclusive partnership with Applied Pharmaceutical Innovations, the company has access to a Health Canada Scheduled 1 Drugs and Substances Dealer’s License Mydecine has a five-year master collaboration research agreement with Johns Hopkins University to research novel psychedelic therapies for mental health and addiction disorders Research out of Johns Hopkins University has shown promising efficacy data using psilocybin as a smoking cessation treatment with…

TuesdayOct 26, 2021 1:30 pm

Activists in Oakland Launch Plan to Legalize Sales of Psychedelic Substances

Activists in Oakland are hoping to establish a community-based model through which individuals could legally buy entheogenic substances from local producers. This will expand Oakland’s present psychedelics decriminalization law. The California city became the first city in the United States to decriminalize a wide range of psychedelic substances, including ayahuasca and psilocybin, in 2019. Decriminalize Nature and other activist groups have been behind various local psychedelic reform efforts across the country, enacting decriminalization measures in states such as Washington, Michigan, Massachusetts and California. Thus far, local legislators have approved a second measure that builds upon the initial Oakland decriminalization of…

MondayOct 25, 2021 11:00 am

DEA Announces Significant Increase in Psychedelic, Cannabis Production Quotas for Next Year

The DEA is suggesting a significant increase to the legal production of psychedelics such as DMT, MDMA, LSD, psilocybin and cannabis, may be for use in research in 2022. In a notice, the Drug Enforcement Administration stated that there had been a considerable increase in the use of Schedule I controlled substances for clinical trial and research purposes, which is why it would like to authorize manufacturers to meet the increasing demand. The agency had already increased its proposed 2021 quota for psilocybin and marijuana last month. Now, it would like a wider array of psychedelic substances and substantially higher…

FridayOct 22, 2021 1:15 pm

Study Finds Diabetes, Heart Disease Risk Drops Among Psychedelics Users

A new study has found that individuals who have consumed a psychedelic substance at least once in their lives have decreased chances of developing diabetes or heart disease. The study was reported in the “Scientific Reports” journal. University of Oxford’s Otto Simonsson, the author of the study, stated that prior research had discovered links between lower chances of having hypertension and being obese or overweight and lifetime use of classic psychedelics, noting that hypertension and obesity were cardio-metabolic disease risk factors. Simonsson explained that the purpose of the research was to find the association between cardio-metabolic ailments such as heart…

ThursdayOct 21, 2021 12:30 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announced Inclusion in AdvisorShares Psychedelics ETF; KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

Tryp announced its inclusion in the AdvisorShares Psychedelics ETF The company hopes that its participation will open it up to a more diverse shareholder base and broaden its life science exposure Tryp’s presentation at the KCSA Virtual Investor Conference will also be available for on-demand viewing over the next 90 days Launched back in September 2021, the AdvisorShares Psychedelics Exchange-Traded Fund (“ETF”) has been actively trading, focusing on enterprises that have devoted a significant proportion of their assets to psychedelic drug development. Operating under the ticker symbol “PSIL” on the New York Stock Exchange (“NYSE”) Arca exchange, this fund has…

ThursdayOct 21, 2021 11:30 am

The Psychedelics Sector Could Revolutionize Work

The psychedelics industry is flourishing and growing at a rapid rate as more states move to decriminalize the substances while others push for legalization. In the last few years, the market has seen significant growth in the number of drug-development companies that seek to get psychedelic compounds to be approved by the FDA. Projections show that in the next five years, psilocybin, which is the main active ingredient in magic mushrooms, and MDMA, which is also known as ecstasy, will be legal for prescription. Various studies have found that these substances possess medicinal benefits that may help treat various mental…

WednesdayOct 20, 2021 2:45 pm

Study Finds That Pain Distribution Could Influence Patient Outcomes

A new study has found that reporting pain distribution on a map can help classify patients into subgroups that are linked to differences in pain impact, pain quality, pain intensity and clinically relevant outcomes. The study’s findings were published in the “Plos One” journal. Normally, the distribution of chronic pain across an individual’s body is used together with other symptoms and signs to diagnose and treat patients. Recent research on fibromyalgia shows that pain syndromes that are typically viewed as separate entities may share relevant features, particularly regarding the influence of the distribution of pain on outcomes. For their study,…

WednesdayOct 20, 2021 1:42 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Application Amid ‘New Era’ of Psychedelic Medicine

Substances such as psilocybin, ketamine and LSD are edging into mainstream culture, setting the stage for a paradigm shift in modern medicine Cybin has filed an international patent application covering methods for the delivery of psychedelic medications by inhalation The company is pursuing the effectiveness of using inhalation as a delivery method for psychedelic medications Earlier this month, a Time magazine article reported on the “new era” of psychedelic medicine (https://ibn.fm/bfC3u). On the leading edge of this collective breakthrough is Cybin (NEO: CYBN) (NYSE American: CYBN), a company focused on progressing psychedelic therapeutics, addressing the mental health crisis and transforming the…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000